Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 211.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 44,818 shares of the company's stock after purchasing an additional 30,444 shares during the period. Schroder Investment Management Group's holdings in Vaxcyte were worth $3,675,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DnB Asset Management AS boosted its stake in shares of Vaxcyte by 21.6% during the 4th quarter. DnB Asset Management AS now owns 7,067 shares of the company's stock worth $579,000 after acquiring an additional 1,255 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Vaxcyte by 30.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,017,845 shares of the company's stock worth $83,321,000 after purchasing an additional 236,940 shares in the last quarter. Norges Bank purchased a new position in Vaxcyte in the 4th quarter worth approximately $90,069,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Vaxcyte by 25.2% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 75,472 shares of the company's stock worth $6,405,000 after purchasing an additional 15,200 shares in the last quarter. Finally, Prudential Financial Inc. lifted its stake in Vaxcyte by 32.2% in the 4th quarter. Prudential Financial Inc. now owns 127,771 shares of the company's stock worth $10,459,000 after purchasing an additional 31,118 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Vaxcyte Stock Down 5.2 %

PCVX traded down $1.59 on Thursday, reaching $29.21. The company had a trading volume of 319,509 shares, compared to its average volume of 1,170,304. Vaxcyte, Inc. has a 1 year low of $27.80 and a 1 year high of $121.06. The stock has a market capitalization of $3.76 billion, a PE ratio of -6.35 and a beta of 1.26. The stock has a 50-day moving average price of $68.64 and a 200-day moving average price of $86.91.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Finally, Bank of America dropped their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $136.50.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total value of $692,080.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,250 shares of company stock worth $3,170,738. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.